Skip to content

Search Results

No Matching Results

    Recently Viewed


      HomeJohnson & Johnson Issues Statement on ZYTIGA® Inter Partes Reviews

      Johnson & Johnson Issues Statement on ZYTIGA® Inter Partes Reviews

      Share Article
      share to

      New Brunswick, NJ (January 17, 2018) – Johnson & Johnson issued the following statement regarding today’s Inter Partes Reviews regarding ZYTIGA® (abiraterone acetate):

      “We are disappointed in and strongly disagree with the U.S. Patent and Trademark Office’s (USPTO) decisions relating to ZYTIGA® as part of the Inter Partes Reviews. We are evaluating our options with respect to a request for rehearing and/or appeal to the Court of Appeals for the Federal Circuit. We believe the ‘438 patent is valid and will continue to vigorously defend it.”

      Inter Partes Review decisions by the USPTO do not result in termination of a 30-month stay triggered under the Hatch-Waxman Act by the timely filing of a patent infringement lawsuit against a generic ANDA applicant.

      About Johnson & Johnson
      Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 134,100 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

      Press Contacts:
      Ernie Knewitz
      (732) 524-6623
      (917) 697-2318 (M)

      Investor Contacts:
      Joseph J. Wolk
      (732) 524-1142

      Lesley Fishman
      (732) 524-3922

      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.